Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An index of net bone formation relative to resorption is associated with incident fracture during the menopause transition and postmenopause.

JBMR plus·2026
Same author

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

JAMA·2026
Same author

Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis.

JBMR plus·2026
Same author

Natural history of thyroid function in ageing: an individual participant data analysis of 137 488 participants from 31 prospective cohort studies.

The lancet. Diabetes & endocrinology·2026
Same author

Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical Studies.

Journal of clinical medicine·2026
Same author

Monte Carlo Resampling Validates Use of Bone Mineral Density Change as Surrogate to Replace Fracture in Future Randomized Trials of Osteoporosis Treatments: Results From SABER.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Related Experiment Video

Updated: Jun 27, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease

Jennifer S Walsh1, Richard Eastell, Nicola F Peel

  • 1Academic Unit of Bone Metabolism, Northern General Hospital, Herries Road, Sheffield, S5 7AU, United Kingdom. jenniferwalsh@doctors.org.uk

Fertility and Sterility
|November 18, 2008
PubMed
Summary
This summary is machine-generated.

Depot medroxyprogesterone acetate (DMPA) use in women over 34 did not lead to bone mineral density loss. Increased bone turnover markers in DMPA users did not correlate with changes in bone mineral density.

More Related Videos

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
07:20

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

Related Experiment Videos

Last Updated: Jun 27, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
07:20

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Reproductive Health

Background:

  • Depot medroxyprogesterone acetate (DMPA) is a widely used contraceptive.
  • Concerns exist regarding its potential impact on bone mineral density (BMD) after peak bone mass.
  • Understanding bone turnover markers in relation to BMD changes is crucial for long-term safety assessments.

Purpose of the Study:

  • To investigate the association between elevated bone turnover markers and bone mineral loss in established DMPA users post-peak bone mass.
  • To determine if bone turnover markers can predict bone loss in women using DMPA.

Main Methods:

  • A three-year, observational, longitudinal study conducted in general practice and family planning clinics.
  • Participants included established DMPA users (n=23), discontinuers (n=14), and controls (n=27), all women over age 34.
  • Changes in spine and hip bone mineral density (BMD) were the primary outcome measures.

Main Results:

  • Despite elevated biochemical markers of bone turnover in DMPA users, no significant decrease in BMD was observed.
  • Bone turnover markers did not demonstrate a correlation with changes in BMD over the study period.
  • These findings suggest that increased bone turnover does not necessarily translate to bone loss in this cohort.

Conclusions:

  • A single normal BMD measurement in established DMPA users after peak bone mass may offer reassurance for continued use.
  • Measuring bone turnover markers is not a reliable predictor of bone loss in women using DMPA.
  • Further research may explore alternative markers or long-term BMD trajectories.